Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (28.7), the stock would be worth HK$-7.44 (124% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -119.8 | HK$31.02 |
0%
|
| Industry Average | 28.7 | HK$-7.44 |
-124%
|
| Country Average | 28.8 | HK$-7.46 |
-124%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
Shanghai MicroPort MedBot Group Co Ltd
HKEX:2252
|
32B HKD | -119.8 | -113.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 62.8 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 21.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 30.7 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 22.8 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 25.9 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 33.6 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 20.9 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 43.2 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 22.3 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 16.9 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.5 |
| Median | 28.8 |
| 70th Percentile | 57 |
| Max | 307 555.7 |
Other Multiples
Shanghai MicroPort MedBot Group Co Ltd
Glance View
Shanghai MicroPort MedBot Group Co Ltd is a dynamic player in the medical innovation sector, strategically positioned at the crossroads of advanced technology and healthcare. Born out of a vision to revolutionize surgical practices, MedBot has dedicated itself to the development and commercialization of robotic-assisted systems. The company leverages cutting-edge research and development to create robotic platforms that aid surgeons in performing complex procedures with enhanced precision and control. Operating in a field where precision is paramount, MedBot's products are designed to minimize complications and reduce recovery times, catering to a global demand for improved surgical outcomes. MedBot generates its revenue by selling these sophisticated surgical robots to hospitals and healthcare institutions worldwide. Beyond the initial sale, the company benefits from offering ongoing service contracts, training, and support to ensure seamless integration and optimal performance of their products. Additionally, it capitalizes on the sale of consumables and replacement parts required for the long-term operation of their systems. Through its commitment to innovation and focus on addressing the complexities of surgical procedures, Shanghai MicroPort MedBot Group has carved out a distinctive niche, continually expanding its influence within the expanding scope of minimally invasive surgery.
